UB Paderborn / Katalog / Suche / in CDI

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Journal of clinical oncology, 2021-10, Vol.39 (30), p.3391-3402

2021

Volltextzugriff (PDF)

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Cancer discovery, 2020-08, Vol.10 (8), p.1194-1209

2020

Volltextzugriff (PDF)

The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore

The Journal of pharmacology and experimental therapeutics, 2002-11, Vol.303 (2), p.858

2002

Volltextzugriff (PDF)

The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase

Cellular signalling, 2000-06, Vol.12 (6), p.405-411

2000

Volltextzugriff (PDF)

Regulation of TNF‐α and IFN‐γ induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease

The FASEB journal, 2004-01, Vol.18 (1), p.191-193

2004

Volltextzugriff (PDF)

Small-molecule inhibitors of NF- κB for the treatment of inflammatory joint disease

Current Opinion in Pharmacology, 2002-06, Vol.2 (3), p.316-321

2002

Volltextzugriff (PDF)

Human Calcium-independent Phospholipase A2 Mediates Lymphocyte Proliferation

The Journal of biological chemistry, 2000-11, Vol.275 (46), p.35692-35698

2000

Volltextzugriff (PDF)

Cytosolic 85-kDa Phospholipase A2-mediated Release of Arachidonic Acid Is Critical for Proliferation of Vascular Smooth Muscle Cells

The Journal of biological chemistry, 1997-11, Vol.272 (48), p.30504-30511

1997

Volltextzugriff (PDF)

Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9008-9008

2022

Volltextzugriff (PDF)

MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study

Annals of oncology, 2022-07, Vol.33, p.S482

2022

Volltextzugriff (PDF)

Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.166-171

2023

Volltextzugriff (PDF)

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9006-9006

2021

Volltextzugriff (PDF)

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9512-9512

2020

Volltextzugriff (PDF)

Depletion of Human Monocyte 85-kDa Phospholipase A2 Does Not Alter Leukotriene Formation

The Journal of biological chemistry, 1997-01, Vol.272 (2), p.759-765

1997

Volltextzugriff (PDF)

Anti-human RP105 sera induces lymphocyte proliferation

Journal of leukocyte biology, 1999-01, Vol.65 (1), p.43-49

1999

Volltextzugriff (PDF)

IS1-4. Amivantamab in EGFR Exon 20 Insertion Mutant NSCLC : Asian Subgroup Analysis from the CHRYSALIS Study

Japanese Journal of Lung Cancer, 2021-10, Vol.61 (6), p.537-537

2021

Volltextzugriff (PDF)

Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis

The Journal of pharmacology and experimental therapeutics, 2000-12, Vol.295 (3), p.1061

2000

Volltextzugriff (PDF)

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage

Cancer research (Chicago, Ill.), 2000-02, Vol.60 (3), p.566-572

2000

Volltextzugriff (PDF)

Coexistence of two biochemically distinct phospholipase A2 activities in human platelet, monocyte, and neutrophil

Biochemistry and cell biology, 1993-07, Vol.71 (7-8), p.331

1993

Volltextzugriff (PDF)

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC

Cancer discovery, 2020-05

2020

Volltextzugriff (PDF)

Manipulation of Distinct NFκB Proteins Alters Interleukin-1β-induced Human Rheumatoid Synovial Fibroblast Prostaglandin E2 Formation

The Journal of biological chemistry, 1996-12, Vol.271 (49), p.31496-31501

1996

Volltextzugriff (PDF)

Suppression of monocyte 85-kDa phospholipase A2 by antisense and effects on endotoxin-induced prostaglandin biosynthesis

The Journal of biological chemistry, 1994-10, Vol.269 (42), p.25999-26005

1994

Volltextzugriff (PDF)

Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease

Current opinion in pharmacology, 2002-06, Vol.2 (3), p.316-321

2002

Volltextzugriff (PDF)

Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation

The Journal of pharmacology and experimental therapeutics, 2005-01, Vol.312 (1), p.373

2005

Volltextzugriff (PDF)

Suppression of human synovial fibroblast 85 kDa phospholipase A2 by antisense reduces interleukin-1 beta induced prostaglandin E2

Journal of rheumatology, 1996-03, Vol.23 (3), p.420

1996

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore

The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase

Regulation of TNF‐α and IFN‐γ induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease

Small-molecule inhibitors of NF- κB for the treatment of inflammatory joint disease

Human Calcium-independent Phospholipase A2 Mediates Lymphocyte Proliferation

Cytosolic 85-kDa Phospholipase A2-mediated Release of Arachidonic Acid Is Critical for Proliferation of Vascular Smooth Muscle Cells

Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study

MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study

Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC)

Depletion of Human Monocyte 85-kDa Phospholipase A2 Does Not Alter Leukotriene Formation

Anti-human RP105 sera induces lymphocyte proliferation

IS1-4. Amivantamab in EGFR Exon 20 Insertion Mutant NSCLC : Asian Subgroup Analysis from the CHRYSALIS Study

Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage

Coexistence of two biochemically distinct phospholipase A2 activities in human platelet, monocyte, and neutrophil

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC

Manipulation of Distinct NFκB Proteins Alters Interleukin-1β-induced Human Rheumatoid Synovial Fibroblast Prostaglandin E2 Formation

Suppression of monocyte 85-kDa phospholipase A2 by antisense and effects on endotoxin-induced prostaglandin biosynthesis

Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease

Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation

Suppression of human synovial fibroblast 85 kDa phospholipase A2 by antisense reduces interleukin-1 beta induced prostaglandin E2

Suchergebnisse filtern